Svante and Mercer International Advance Carbon Capture Project at Alberta Pulp Mill
1.5.2025 03:25:00 CEST | Business Wire | Press Release
Svante Technologies Inc. (Svante), a leader in carbon capture and removal technology, today announced that its joint carbon capture and storage project with Mercer International Inc. (Mercer) has advanced to the Front-end Engineering and Design Phase 2 (FEL-2). Also known as Pre-FEED, this phase involves engineering, cost estimation, and risk analysis to evaluate the project's commercial viability. Mercer is a global producer of sustainably sourced forest products, including pulp, lumber, mass timber, biomass-based green energy, and bioextractives.
The carbon capture project targets biogenic CO2 emissions from Mercer’s Peace River pulp mill, where the biomass (fibre) is sourced from sustainably managed forests. Advancing to the Pre-FEED stage will support further development of the integrated design, cost estimates, and risk assessments—key steps toward a final investment decision and potential implementation. This milestone reflects the growing momentum for carbon capture solutions within Canada’s pulp and paper sector.
Matt Stevenson, Chief Revenue Officer at Svante, said the advancement to Pre-FEED demonstrates the company’s momentum in the pulp and paper sector. “We are thrilled to advance this project with Mercer at their Peace River mill to the pre-FEED stage. This will demonstrate the viability of our technology for the pulp and paper industry in Western Canada, enabling carbon removal at scale by working in tandem with nature and highlighting our commitment to providing sustainable solutions for an industrial future.”
Svante’s second-generation carbon capture technology is engineered for commercial-scale deployment in industrial environments such as pulp mills—settings where integration must be cost-effective, modular, and resilient to operational variability. As decarbonization efforts intensify across heavy industry, this project offers a timely opportunity to demonstrate how advanced capture systems can be applied within existing infrastructure.
At the core of Svante’s solution is its structured sorbent filter system, which uses solid materials coated with metal-organic frameworks (MOFs)—nanomaterials specifically designed to selectively capture CO₂ molecules. These filters represent a meaningful evolution over earlier carbon capture systems, offering reduced energy requirements and broader industrial applicability.
Key Technical Features
Utilizing a novel carbon capture technology for commercial deployment, Svante's second-generation capture technology maximizes low-grade waste heat from pulp mills, reducing energy consumption and increasing cost-effectiveness. Svante’s technology also provides:
- Robust Particulate Handling: Structured adsorbent filters are highly resistant to particulate fouling, ensuring consistent performance in challenging pulp mill environments.
- Environmentally Responsible Design: Materials are free from toxic emissions and degradation byproducts. The company’s sorbent-based filters are designed to be recyclable, minimizing environmental impact.
- Rapid Response to Operational Fluctuations: Svante's rapid capture process adapts quickly to intermittent operations, eliminating the need for onsite liquid solvent storage and makeup.
- Compact and Modular Design: Minimizes capture plant vertical footprint and visual impact, offering significant benefits for site integration.
Additional Project Highlights
- Leveraging Clean Power Production from the Mercer Peace River Mill: The project’s energy requirements will be met by low-carbon electricity generated onsite, with recovered waste heat further increasing the net CO₂ emissions avoided.
- Sustainably Sourced Fibre: The mill sources its fibre from sustainably managed forests certified to SFI.
- Permanent and Safe CO2 Storage Within Alberta’s Abundant Sequestration Resource: Alberta has proven, abundant geologic reservoirs—formations capable of securely storing CO₂—supported by a government-enabled regulatory framework that includes robust permitting processes and liability management tools.
Bill Adams, Chief Sustainability Officer at Mercer, said, "The collaboration with Svante reflects Mercer's drive to pursue climate innovation opportunities that align with our business goals. Examining carbon capture in a commercial mill setting gives us a valuable opportunity to assess its long-term potential—both for our own operations and for advancing decarbonization pathways across the industry.”
The project represents a meaningful step toward enabling industrial carbon capture in Canada’s pulp and paper sector, advancing practical climate solutions from concept to potential deployment.
About Svante
Svante is a purpose-driven, leading carbon capture and removal solutions provider. The Vancouver, Canada-based company manufactures nanoengineered filters and modular rotary contactor machines that capture and remove CO2 from industrial emissions and the air in an environmentally responsible manner. Svante is on TIME & Statista’s Top Greentech Companies of 2025, the 2025 Global Cleantech 100, the XPRIZE Foundation’s XB100 – World’s Top 100 Deep Tech Companies, and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies.
For more information, visit www.svanteinc.com and follow Svante on LinkedIn at www.linkedin.com/svantesolutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250430255260/en/
Contacts
Media
Colleen Nitta
Director of Marketing & Communications
cnitta@svanteinc.com - Cnitta@svanteinc.com
604-970-2813
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom